Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults between 55 and 85 years of age at the time of signing consent, of any gender
- People who score between 20 and 28 on a memory and thinking test called the Korean Mini-Mental State Examination (K-MMSE)
- People who score between 0.5 and 1 on a dementia rating scale called the Clinical Dementia Rating (CDR), with a memory sub-score of at least 0.5
- People whose brain scan (PET scan) shows the presence of amyloid, a protein associated with Alzheimer's disease
Who may not be able to join:
- People who have significant medical conditions other than Alzheimer's disease that could affect memory or thinking, including past or current brain or nervous system diseases, brain infections, structural brain abnormalities seen on MRI, thyroid problems, or low vitamin B12 levels (confirm with trial site)
- People with a history of seizures or epilepsy
- People with a history or suspected history of alcohol or drug misuse or dependence
- People with a history of psychiatric conditions such as schizophrenia, bipolar disorder, or major depression, where symptoms are currently active
- People who have been diagnosed with cancer, or had cancer return, within the past 5 years
- People who have had a major heart or cardiovascular event in the past 12 months
- People with a heart or blood vessel condition that requires them to take blood-thinning medication
- People who have had a serious or active infection requiring antibiotic or antiviral treatment within the past 4 weeks, or who are expected to need such treatment during the study
- People who have had significant digestive or stomach problems within the past 3 months, or conditions that affect how the body absorbs nutrients
- People who have received any Alzheimer's disease treatment aimed at slowing the disease (not just managing symptoms) within the past year
- People who have started, stopped, or changed the dose of any dementia symptom medication within the past 12 weeks
- People who have regularly used medications that affect the brain or thinking within the past 8 weeks
- People who have regularly used medications that may change the balance of bacteria in the gut within the past 4 weeks
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Woo Jung Kim, Yonsei University Yongin Severance Hospital
Phone: +82221940510
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change from baseline in the ADAS-Cog 14 total score at Weeks 12 and 24; Change from baseline in the ADAS-Cog 14 memory box score at Weeks 12 and 24; Change from baseline in the ADCS-MCI-ADL score at Weeks 12 and 24; Change from baseline in the K-MMSE score at Weeks 12 and 24; Change from baseline in the Global Clinical Dementia Rating (CDR) score at Week 24; Change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score at Week 24; Change from baseline in amyloid PET imaging biomarkers at Week 24; Change from baseline in blood-based Alzheimer's disease-related biomarkers at W...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.